ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma
Allergy Mar 21, 2018
Yu QN, et al. - Researchers herein sought to assess the group 2 innate lymphoid cell (ILC2) activity after glucocorticoid therapy in asthma patients. Findings demonstrated that glucocorticoid, by regulating ILC2s via MEK/JAK-STAT signaling pathways, could be effective in treating asthma.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
